CA Patent

CA1090256A — Medicament pack and agent for the treatment of climacteric deficiency symptoms

Assigned to Bayer Pharma AG · Expires 1980-11-25 · 45y expired

What this patent protects

ABSTRACT OF THE DISCLOSURE A medicament pack and agent for the treatment of climacteric deficiency symptoms. The pack comprises a pharmaceutical treatment pack for the treatment of climacteric deficiency symptoms, which comprises in or on a support member, unit dosage forms of a…

USPTO Abstract

ABSTRACT OF THE DISCLOSURE A medicament pack and agent for the treatment of climacteric deficiency symptoms. The pack comprises a pharmaceutical treatment pack for the treatment of climacteric deficiency symptoms, which comprises in or on a support member, unit dosage forms of an E2 oestrogen, an E3 oestrogen and a gestagen, which provided (I) (a) a first set of 10 - 12 daily dosages of an E2 oestrogen and (b) a first set of 10 - 12 daily of an E3 oestrogen, the ratio of the daily average dosage of E2 oestrogen to the average daily dosage of E3 oestrogen being from 2:1 to 1:8, (II)(a) a second set of 9 - 11 daily dosages of E2 oestrogen, to complete 20 - 22 daily dosages, and (b) a second set of 9 - 11 daily dosages of E3 oestrogen, to complete 20 - 22 daily dosages, the ratio of the average daily dosage of E2 oestrogen to the average daily dosage of E3 oestrogen being from 2:1 to 1:8, and (c) a set of 9 - 11 daily dosages of a gestagen, and if desired, (III) a third set of 6 - 8 daily dosages of E3 oestrogen or of hormone-free preparations, to complete 28 daily dosages, or of objects indicating 6 - 8 days of no hormone treatment, the sets being located in a particular order, together with indications and/or instructions to indicate and facilitate a treatment consisting of the administration to a human female on each of 10 - 12 successive days of one of the daily dosages Ia and one of the daily dosages Ib, on each of the immediately following 9 - 11 successive days, to complete 20 - 22 days, one of daily dosages IIa, one of the daily dosages IIb and one of the daily dosages IIc, and on each of the immediately following 6 - 8 successive days, to complete 28 days, one of the E3 oestrogen or hormone-free daily dosages III or no administration of hormone.

Drugs covered by this patent

Patent Metadata

Patent number
CA1090256A
Jurisdiction
CA
Classification
Expires
1980-11-25
Drug substance claim
No
Drug product claim
No
Assignee
Bayer Pharma AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.